uploads/2018/01/Analysts-recommendations-1.png

What Analysts Recommend for Bristol-Myers Squibb in January 2018

By

Updated

Recent developments

In December 2017, Bristol-Myers Squibb (BMY) entered a clinical trial collaboration with Taris Biomedical to evaluate the safety, tolerability, and efficacy of Taris Biomedical’s investigational product TAR-200 in combination with Bristol-Myers Squibb’s Opdivo for the treatment of individuals with muscle-invasive bladder cancer (or MIBC) who have been recommended to have a radical cystectomy. Around 2.7 million individuals worldwide have bladder cancer, and there currently are only a few treatment options available.

Article continues below advertisement

Analysts’ recommendations

Of the 24 analysts that were tracking Bristol-Myers Squibb in January 2018, six analysts recommended a “strong buy,” while four recommended a “buy.” 12 analysts recommended a “hold,” while two analysts recommended a “sell.”

On January 16, 2018, Bristol-Myers Squibb had a consensus 12-month target price of $64.05, which represents a 2% return on investment over the next 12 months. The SPDR S&P 500 ETF (SPY) invests ~0.44% of its total portfolio holdings in Bristol-Myers Squibb.

Peer ratings

Of the 24 analysts tracking Johnson & Johnson (JNJ) in January 2018, ~50% of analysts recommended some form of a “buy” rating. On January 16, 2018, Johnson & Johnson had a consensus 12-month target price of $148.36, which represents a ~1.8% return on investment over the next 12 months.

Of the 24 analysts tracking Pfizer (PFE) in January 2018, ~54% of analysts recommended some form of a “buy” rating. On January 16, 2018, Pfizer had a consensus 12-month target price of $38.43, which represents a 4.6% return on investment over the next 12 months.

Of the 23 analysts tracking Merck (MRK) in January 2018, ~57% of analysts recommended some form of a “buy” rating. On January 16, 2018, Merck had a consensus 12-month target price of $65.29, which represents a 5.8% return on investment over the next 12 months.

Advertisement

More From Market Realist